---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049199"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:35:00.013869+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InspireMD enrolls first patient in CGUARDIANS II pivotal TCAR study for CGuard Prime

## Summary
- First patient enrolled by Dr. Patrick Muck at Good Samaritan Hospital (TriHealth, Cincinnati).
- Prospective, single-arm study: 50+ evaluable patients; acute device/technical success endpoints.
- CEO targets FDA approval for CGuard Prime CAS indication in H1 2025; TCAR market ~30,000 procedures/year.
- Over 60,000 CGuard devices sold globally; MicroNet mesh cited for protective outcomes.

## SEC filing metadata
- accession: 0001493152-24-049199
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315224049199/0001493152-24-049199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315224049199/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049199
- JSON: https://secwatch.observer/filing/0001493152-24-049199.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.